Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (Nasdaq: JAZZ) on the exploration of a novel combination ...
The MarketWatch News Department was not involved in the creation of this content. -- Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results